RNA· Health Care› Biotechnology

Atrium Therapeutics, Inc.

$8.16

+2.00% today

$140M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Not enough history to read yet

Setup score

—

Momentum

Steady

Edge

—

Is RNA early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2026-02-27 → 2026-10-22

S? 34w

2026-02-272026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S? 34w current

Total tracked: 34 weeks across 1 stage run.

RNA among Biotechnology581st of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…581	RNAAtrium Therapeutics, Inc.	—	—	−2.0%

vs 52W High

—

Stock is basing below old highs. A volume-backed breakout to new highs would be the Stage 2 signal to watch.

Stage Maturity

Week 33

1w13w26w

Week 33, mature

How long this stock has been basing. Longer bases can produce stronger breakouts, but the breakout itself is the signal.

vs 200 DMA

—

Stock is testing its 200 DMA as part of the base. Reclaiming and holding above it is a key Stage 2 prerequisite.

Rel Volume

0.57x

vs 50-day avg

Volume in Stage 1 basing is typically quiet. A surge in volume on an upside breakout is the signal to watch.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-2.0%

-29.0%

-41.1%

YTD

—

Scan Membership

Not in any current scan.

Recent Stage Timeline

2026-10-22S—

Wk 33 · Vol 0.57x

2026-10-21S—

Wk 33 · Vol 0.57x

2026-10-20S—

Wk 33 · Vol 0.97x

2026-10-19S—

Wk 33 · Vol 0.82x

2026-10-16S—

Wk 33 · Vol 0.64x

2026-10-15S—

Wk 32 · Vol 0.44x

2026-10-14S—

Wk 32 · Vol 0.91x

2026-10-13S—

Wk 32 · Vol 0.81x

2026-10-12S—

Wk 32 · Vol 0.30x

2026-10-09S—

Wk 32 · Vol 0.72x

2026-10-08S—

Wk 31 · Vol 2.31x

2026-10-07S—

Wk 31 · Vol 0.33x

Moving averages & range

50 DMA

$10.34

200 DMA

—

52W High

—

52W Low

—

5D Low

$7.61

Resistance levels (recent highs)

20d High

$8.42

60d High

$14.60

120d High

$14.60

250d High

—

Next resistance

+3.2%

to 20d High

Dividend Yield

0.00%

P/B 0.7

Atrium Therapeutics: quick answers

Which sector and industry is Atrium Therapeutics in?

Atrium Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. It has a research collaboration and license agreement with Bristol-Myers Squibb Company and Eli Lilly and Company. The company was incorporated in 2025 and is headquartered in San Diego, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.